GlassScriptPhysician profile
Monique J Majewski
NPI 1013296599
$8,659.00
in general payments reported to CMS, 2019-2025
29 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,309 · 2022: $1,278 · 2023: $1,661 · 2024: $2,356 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,785 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.03 |
| Education | $286.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,741.73 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,208.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $884.52 | 2021-2025 | Sotyktu |
| Genzyme Corporation | $787.95 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $695.21 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $479.61 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $406.10 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $352.04 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $343.30 | 2021-2025 | |
| Galderma Laboratories, L.P. | $329.00 | 2021-2025 | Nemluvio |
| Incyte Corporation | $289.14 | 2021-2025 | Opzelura |
| Pfizer INC. | $281.98 | 2021-2025 | |
| Lilly USA, LLC | $227.70 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $143.38 | 2021-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $84.84 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $63.99 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.98 | 2023-2024 | Spevigo, Cyltezo |
| Biofrontera INC. | $47.17 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $41.36 | 2023-2025 | Zoryve |
| Almirall LLC | $38.81 | 2021-2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $22.36 | 2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $21.89 | 2022 | |
| Botanix Sb INC | $20.52 | 2025 | Sofdra |
| Sandoz INC. | $20.37 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.10 | 2023 | Arazlo, Jublia |
| Merz North America, INC. | $18.04 | 2023 | Xeomin |
| Journey Medical Corporation | $14.88 | 2023 | |
| Krystal Biotech INC | $14.51 | 2023 | Vyjuvek |
| Organon LLC | $4.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Majewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.